For a patient with relapsed FLT3 positive AML on HMA and venetoclax, is there ever a role for the addition of midostaurin to the treatment regimen to improve response rate?
Answer from: Medical Oncologist at Academic Institution
Short answer is no. The safety of the combination is unknown and there’s also not an indication for Midostaurin in relapsed AML. The trial that got Midostaurin approved was for combination with 7+3 in newly diagnosed patients. HMA+ venetoclax has better response frontline compared to relapsed/...
Comments
Medical Oncologist at Kaiser Permanente Moanalua Medical Center Thanks for your response! Appreciated.
Thanks for your response! Appreciated.